文献速递眼底病与葡萄膜炎

口服姜黄素降低孔源性视网膜脱离修复术后增生性玻璃体视网膜病变风险

ORAL CURCUMIN TO REDUCE RISK OF PROLIFERATIVE VITREORETINOPATHY FOLLOWING RHEGMATOGENOUS RETINAL DETACHMENT REPAIR.
PubMed 文献 · Retina · 2024-01-01

回顾性观察性病例系列纳入32眼(31例)高危孔源性视网膜脱离修复术后开始口服姜黄素的患者,推荐剂量为500 mg每日两次用30天、随后500 mg每日一次用60天。术后6个月内2眼(6.3%)发生增生性玻璃体视网膜病变相关视网膜脱离,单次手术视网膜复位率为87.5%。作者认为口服姜黄素耐受良好,值得进一步研究其降低增生性玻璃体视网膜病变风险的潜力。

要点

  • 32眼高危孔源性视网膜脱离修复术后口服姜黄素,6个月内增生性玻璃体视网膜病变相关脱离2眼(6.3%)。
  • 单次手术视网膜复位率87.5%,无硅油者92.6%(25/27),Grade C增生性玻璃体视网膜病变者91.7%。
  • 术后7眼(21.9%)发生黄斑前膜,其中3眼(9.4%)行黄斑前膜剥除;无患者出现胃肠道不适或贫血。

核心结论

  • 这项概念验证性临床研究提示口服姜黄素耐受良好,值得进一步研究其降低高危眼孔源性视网膜脱离修复术后增生性玻璃体视网膜病变风险的潜力。

研究设计与样本

  • 回顾性观察性病例系列,纳入高危孔源性视网膜脱离修复术后开始口服姜黄素的患者32眼(31例)。
  • 推荐剂量为500 mg每日两次用30天,随后500 mg每日一次用60天。

主要发现

  • 术后6个月内2眼(6.3%)发生增生性玻璃体视网膜病变相关视网膜脱离,另2眼(6.3%)因新裂孔无增生性玻璃体视网膜病变而再脱离。
  • 总体单次手术视网膜复位率为87.5%,无硅油者单次手术视网膜复位率为92.6%(25/27)。
  • 12例Grade C增生性玻璃体视网膜病变相关视网膜脱离中,单次手术视网膜复位率为91.7%。
  • 术后7眼(21.9%)发生黄斑前膜,其中3眼(9.4%)行黄斑前膜剥除。
  • 无患者出现胃肠道不适或贫血。

临床怎么用

  • 作者认为口服姜黄素耐受良好,值得进一步研究其降低高危眼孔源性视网膜脱离修复术后增生性玻璃体视网膜病变风险的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate outcomes of patients who underwent rhegmatogenous retinal detachment repair and were started on oral curcumin for proliferative vitreoretinopathy (PVR) prevention. METHODS: Retrospective, observational case series of eyes of patients undergoing high-risk rhegmatogenous retinal detachment repair that was started on curcumin postoperatively. Recommended dosage was 500 mg twice daily for 30 days followed by 500 mg daily for 60 days. The primary outcome was recurrent PVR-related rhegmatogenous retinal detachment within 6 months and a single-surgery retinal reattachment rate. Secondary outcomes included epiretinal membrane formation, visual acuity, and curcumin safety profile. RESULTS: Thirty-two eyes of 31 patients met the study inclusion criteria. Postoperatively, 2 eyes developed a PVR-related detachment (6.3%), and 2 eyes redetached due to new breaks without PVR (6.3%). Overall, single-surgery retinal reattachment rate was 87.5%. Single-surgery retinal reattachment rate without silicone oil was 92.6% (25/27). Of the 12 cases with Grade C PVR-related retinal detachment, the single-surgery retinal reattachment rate was 91.7%. Postoperatively, 7 eyes developed an epiretinal membrane (21.9%), of which 3 underwent epiretinal membrane removal (9.4%). No patient had gastrointestinal upset or anemia. CONCLUSION: This proof-of-concept clinical study suggests that oral curcumin is well tolerated and warrants further investigation for its potential to reduce the risk of PVR after rhegmatogenous retinal detachment repair in eyes at higher risk of PVR.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Valikodath N, Woodward R, et al. ORAL CURCUMIN TO REDUCE RISK OF PROLIFERATIVE VITREORETINOPATHY FOLLOWING RHEGMATOGENOUS RETINAL DETACHMENT REPAIR. Retina. 2024. PMID: 39287536. doi:10.1097/IAE.0000000000004182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。